- Home
- VRNA vs CPB Comparison
VRNA vs CPB Comparison
Compare VRNA & CPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNA
- CPB
- Stock Information
- Founded
- VRNA 2005
- CPB 1869
- Country
- VRNA United Kingdom
- CPB United States
- Employees
- VRNA N/A
- CPB N/A
- Industry
- VRNA Biotechnology: Pharmaceutical Preparations
- CPB Packaged Foods
- Sector
- VRNA Health Care
- CPB Consumer Staples
- Exchange
- VRNA Nasdaq
- CPB Nasdaq
- Market Cap
- VRNA 8.3B
- CPB 9.2B
- IPO Year
- VRNA 2017
- CPB N/A
- Fundamental
- Price
- VRNA $106.91
- CPB $31.03
- Analyst Decision
- VRNA Buy
- CPB Hold
- Analyst Count
- VRNA 11
- CPB 16
- Target Price
- VRNA $114.10
- CPB $34.20
- AVG Volume (30 Days)
- VRNA 1.5M
- CPB 5.8M
- Earning Date
- VRNA 11-03-2025
- CPB 09-03-2025
- Dividend Yield
- VRNA N/A
- CPB 5.01%
- EPS Growth
- VRNA N/A
- CPB 6.35
- EPS
- VRNA N/A
- CPB 2.01
- Revenue
- VRNA $221,673,000.00
- CPB $10,253,000,000.00
- Revenue This Year
- VRNA $909.96
- CPB N/A
- Revenue Next Year
- VRNA $76.47
- CPB $1.13
- P/E Ratio
- VRNA N/A
- CPB $15.48
- Revenue Growth
- VRNA N/A
- CPB 6.40
- 52 Week Low
- VRNA $31.09
- CPB $29.39
- 52 Week High
- VRNA $106.94
- CPB $49.11
- Technical
- Relative Strength Index (RSI)
- VRNA 72.60
- CPB 40.61
- Support Level
- VRNA $105.78
- CPB $31.25
- Resistance Level
- VRNA $106.86
- CPB $32.09
- Average True Range (ATR)
- VRNA 0.16
- CPB 0.82
- MACD
- VRNA -0.04
- CPB -0.21
- Stochastic Oscillator
- VRNA 98.26
- CPB 10.07
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
About CPB Campbell Soup Company
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2024 (July year-end), snacks accounted for nearly half of its revenue, followed by soup (28%), other simple meals (17%), and beverages (7%). Outside its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and recently acquired Rao's (a deal that closed in March 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.